Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,198
datasets available to search
ShareScore release 0.9.0
Dataset results
1,198 results for “Vaccination and immunization”
Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study
<p>The data represent the concentrations of specific neutralizing antibodies following infant immunization against yellow fever. We used a microneutralization assay to measure protective antibodies against yellow fever virus in 587 Malian and 436 Ghanaian children vaccinated around age 9 months, and followed for 4.5 years (Mali), or 2.5 and 6 years (Ghana). We standardized antibody concentrations with reference to the yellow fever WHO International Standard.</p> <p>The serum samples used in this study, and the sample metadata included in the present dataset originate from trials of the meningococcal group A conjugate vaccine, MenAfriVac, namely the PsATT-004 (phase II) and Pers-004 (phase IV) studies in Ghana, and the PsATT-007 (phase III) and Pers-007 (phase IV) studies in Mali (clinical trial registry numbers ISRCTN82484612, ISRCTN10763234, PACTR201110000328305, and ISRCTN37623829). MenAfriVac was developed by PATH and Serum Institute India Pvt. Ltd. (SIIPL).</p> <p>This dataset consists of three files:</p> <p>1. Ghana group data | Tab-delimited text file: Yellow_fever_nAb_Ghana.csv</p> <p>2. Mali group data | Tab-delimited text file: Yellow_fever_nAb_Mali.csv</p> <p>3. Data dictionary | PDF file: Yellow_fever_nAb_Data_Dictionary.pdf</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p>
Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
<p>The dataset contains case-based data on invasive pneumococcal disease in Austria, 2009/01 to 2017/02, by year and month of diagnosis, serotype and clinical presentation. Cases are anonymised by using a random ID.</p>
Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland – a multicentre cohort study
<p>For details, see publication</p>
Characterization of the anti-spike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
<p>Participants submitted saliva using the OME-505 collection device (OMNIgene Oral, Ottawa, Canada) every two weeks from vaccination through six months post-dose 3 to detect breakthrough SARS-CoV-2 infections. Viral RNA was extracted using the NucliSENS easyMag automated extraction system from 200ul of saliva in stabilizing solution and eluted in a total volume of 50ul. First strand cDNA synthesis was performed from 5ul of eluted RNA using SuperScript IV VILO Master Mix (Thermo Fisher). Positive specimens were then sequenced. Multiplex tiled amplicon libraries were prepared using the Midnight panel and Rapid barcoding kit RBK-004 (Oxford Nanopore technologies) using previously published protocol. Twelve sample pooled libraries were sequenced on a GridION X5 nanopore sequencer using Flongle adapters. After sequencing, raw data were processed using interARTIC to generate consensus sequences and variant calls. SARS-CoV-2<strong> </strong>lineages were determined using these consensus sequences and the NextClade and Pangolin platforms.</p>
Fig. 1 in Nasal vaccination of six squirrel monkeys (Saimiri sciureus): Improved immunization protocol against Toxoplasma gondii with a nanoparticle-born vaccine
Fig. 1. Schedule of the vaccinal protocol and of the immunological analysis performed on the 6 Saimiris.
Fig. 2. T in Nasal vaccination of six squirrel monkeys (Saimiri sciureus): Improved immunization protocol against Toxoplasma gondii with a nanoparticle-born vaccine
Fig. 2. T-cell immune response analyzed by IFN-γ ELISPOT on PBMC from 6 Saimiris. The results are presented as Spot Forming Units for 106 PBMC (left), before the immunization (T0), one month after the prime, 5 months after the 1st boost and 2 months after the 2nd boost. A representative picture of the ELISPOT plate after the 2nd boost is presented (right). Only 4 animals were analyzed by ELISPOT after the 2nd boost due to blood coagulation in the sampling tubes. Statistical analyses were made by KruskalWallis test, * p <0.05, ** p <0.01.
Fig. 3 in Nasal vaccination of six squirrel monkeys (Saimiri sciureus): Improved immunization protocol against Toxoplasma gondii with a nanoparticle-born vaccine
Fig. 3. Humoral immune response analyzed by ELISA on serum for each Saimiri. The results are presented as optical density (OD) before the immunization (T0), and 2 months after the 2nd boost. Serum from one seropositive and three seronegative humans were used as positive and negative controls, respectively. Cut-off was determined at each dilution, as the mean + 2.5xSD of the negative controls.
DATASET Skin-Based Vaccination: A Systematic Mapping Review of the Types of Vaccines and Methods Used and Immunity and Protection Elicited in Pigs
<p>Dataset listing all publications used in systematic mapping review. This file contains the dataset, a dictionary and values worksheets for the following publication: </p> <p>Skin-Based Vaccination: A Systematic Mapping Review of the Types of Vaccines and Methods Used and Immunity and Protection Elicited in Pigs.</p> <p>Vaccines 2023</p> <p><a href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&size=200&term=C%C3%B3-Rives+I&cauthor_id=36851328">Inés Có-Rives</a> <a href="https://pubmed.ncbi.nlm.nih.gov/36851328/#full-view-affiliation-1">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&size=200&term=Chen+AY&cauthor_id=36851328">Ann Ying-An Chen</a> <a href="https://pubmed.ncbi.nlm.nih.gov/36851328/#full-view-affiliation-1">1</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&size=200&term=Moore+AC&cauthor_id=36851328">Anne C Moore</a> <a href="https://pubmed.ncbi.nlm.nih.gov/36851328/#full-view-affiliation-1">1</a></p> <ul> <li>PMID: 36851328</li> <li>PMCID: <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9962282/">PMC9962282</a></li> <li>DOI: <a href="https://doi.org/10.3390/vaccines11020450">10.3390/vaccines11020450</a></li> </ul> <p>The advantages of skin-based vaccination include induction of strong immunity, dose-sparing, and ease of administration. Several technologies for skin-based immunisation in humans are being developed to maximise these key advantages. This route is more conventionally used in veterinary medicine. Skin-based vaccination of pigs is of high relevance due to their anatomical, physiological, and immunological similarities to humans, as well as being a source of zoonotic diseases and their livestock value. We conducted a systematic mapping review, focusing on vaccine-induced immunity and safety after the skin immunisation of pigs. Veterinary vaccines, specifically anti-viral vaccines, predominated in the literature. The safe and potent skin administration to pigs of adjuvanted vaccines, particularly emulsions, are frequently documented. Multiple methods of skin immunisation exist; however, there is a lack of consistent terminology and accurate descriptions of the route and device. Antibody responses, compared to other immune correlates, are most frequently reported. There is a lack of research on the underlying mechanisms of action and breadth of responses. Nevertheless, encouraging results, both in safety and immunogenicity, were observed after skin vaccination that were often comparable to or superior the intramuscular route. Further research in this area will underlie the development of enhanced skin vaccine strategies for pigs, other animals and humans.</p> <p><strong>Keywords: </strong>epicutaneous; epidermal; intradermal; needle-free; percutaneous; pig; skin; transcutaneous; transdermal; vaccine.</p>
Characterization of the anti-spike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
<p>Research on COVID-19 vaccination in immune-deficient/disordered people (IDP) has primarily focused on cancer and organ transplantation populations. In a prospective cohort of 195 IDP and 35 healthy volunteers, anti-spike IgG was detected in 88% of IDP post-dose 2, increasing to 93% by six months post-dose 3. Despite high seroconversion, median IgG levels for IDP never surpassed 1/3 that of healthy volunteers. IgG binding to Omicron BA.1 was lower than all other variants. Angiotensin-converting enzyme 2 pseudo-neutralization (% inhibition) was only modestly correlated with anti-spike IgG concentration. IgG levels were not significantly altered by participants' use of different mRNA-based vaccines, immunomodulating treatments, and prior SARS-CoV-2 infections. While our data show that three doses of COVID-19 vaccinations induce anti-spike IgG in most IDP, additional doses are needed to achieve the levels of protection in healthy volunteers. Due to the strikingly reduced IgG response to Omicron BA.1, the efficacy of additional vaccinations, including bivalent vaccines, should be studied in this population.</p>
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
ClinicalTrials.gov study NCT04792567. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
ClinicalTrials.gov study NCT01190228. IPD Sharing: YES. Countries: 1. Publications: 1.
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
ClinicalTrials.gov study NCT03746015. IPD Sharing: YES. Countries: 1. Publications: 1.
Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine
ClinicalTrials.gov study NCT02968420. IPD Sharing: NO. Countries: 1. Publications: 2.
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
ClinicalTrials.gov study NCT04952402. IPD Sharing: YES. Countries: 1. Publications: 0.
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup
ClinicalTrials.gov study NCT04084769. IPD Sharing: YES. Countries: 2. Publications: 1.
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adult
ClinicalTrials.gov study NCT04537234. IPD Sharing: YES. Countries: 1. Publications: 1.
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
ClinicalTrials.gov study NCT01488890. IPD Sharing: YES. Countries: 1. Publications: 1.
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults
ClinicalTrials.gov study NCT04498832. IPD Sharing: YES. Countries: 1. Publications: 1.
Characterization of the anti-spike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
Open the record for dataset details and reuse information.
Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon vaccination
<p>Data set accompanying the publication "Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon vaccination".</p> <p>In this study, we utilize high-throughput sequencing to profile the memory CD4 TCRβ repertoire and track vaccine-specific and epitope-specific TCRβ clonotypes following the de novo administration of hepatitis B (HepB) vaccine in healthy HepB-naïve individuals.</p> <p>The data set is comprised out of the following parts:</p> <ul> <li>repTCRb: Folder containing CD4+ TCR repertoire data from volunteers. Some of these samples are also available in ImmuneAccess (https://clients.adaptivebiotech.com/pub/deneuter-2018-cmvserostatus).</li> <li>peptideTCRab: Folder containing peptide-specific or peptide-pool-specific TCR data</li> <li>df_all: Meta and FC data for samples and volunteers</li> <li>freqCD154: CD154-based group definitions</li> <li>groups.csv: Group definitions used for classes</li> </ul>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.